08.00 REGISTRATION & COFFEE 08.20 Opening Speech by: Barrett J. Rollins, MD, PhD Linde Family Professor of Medicine at Harvard Medical School, Chief Scientific Officer at Dana-Farber Cancer Institute 08.45 Deal Making Co-Chaired by: Anne Altmeyer, Vice President, Business Development & Licensing, Oncology, Novartis Pharmaceuticals Dov Hass, Associate, Morgan, Lewis & Bockius LLP Panellists: Dennis Purcell, Founder and Senior Advisor, Aisling Capital Francis Kern, Senior Director of External Scientific Affairs, Daiichi Sankyo Inc. Guillaume Vignon, Director of Global BD Oncology, Merck Serono SA Howard J. Fingert, Senior Medical Director, Business Development & Clinical Intelligence, Takeda Oncology Ji Li, Vice President, Business Development and Licensing, Merck & Co., Inc. John Gustofson, Senior Director, Venture and Early Stage Collaboration, AbbVie Steven Tregay, Chief Executive Officer, Forma Therapeutics Wendy Dwyer, Vice President, Corporate Business Development, Ipsen Bioscience 09.45 10.45 NextGen Immunotherapeutics Co-Chaired by Mara Goldstein, Managing Director & Senior Biotechnology Analyst, Cantor Fitzgerald Raffaele Baffa, Senior Director, Translational and Experimental Medicine, Sanofi Aventis SA Panellists: Doug Plessinger, VP, Clinical and Medical Affair, Argos Therapeutics, Inc. Frank Gleeson, Chief Executive Officer, Fusion Pharmaceuticals Gil Beyen, Chairman and CEO, Erytech Pharma Greg Mayes, CBO, Advaxis Inc. Greg Naeve, Head of Strategic Research Partnerships, Oncology, Pfizer Dragan Cicic, CMO, Actinium Pharmaceuticals. Inc. Marc Mansour, CEO, Immunovaccine Technologies Paul Higham, Managing Director, immatics biotechnologies GmbH Robert Pierce, Chief Scientific Officer, Oncosec Medical COFFEE BREAK Emerging Companies Track 08.45 Cell Source Ltd. 08.55 Office of Therapeutics Alliances, NYU School of Medicine 09.05 Pelican Therapeutics 09.15 Rexahn Pharmaceuticals, Inc. 09.25 SolaranRx, Inc 09.35 tba 09.45 tba 09.55 tba 10.05 tba 10.15 tba 10.25 tba 10.35 tba Presenting Companies TRACK A 11.00 12.00 12.45 Gene & Cell Therapy Co-Chaired by: Maxim Jacobs, Senior Healthcare Analyst, Edison Group Mike Rice, Senior Consultant, Defined Health Panellists: Madhusudan Peshwa, Executive Vice President, Cellular Therapies, MaxCyte, Inc. Mike Khan, CMO, Silence Therapeutics Robert Dillman, Vice-President of Oncology, NeoStem, Inc. Peter Hoang, Senior Vice President BD & Strategy, Bellicum Pharmaceuticals, Inc. Peter Sandor, VP Global Marketing, TA Head Oncology, Amgen Personalized Medicine & Diagnostics Co-Chaired by: Stephen Brozak, Managing Partner and President, WBB Securities, LLC Rowan Chapman, Managing Director, Ventures, GE Healthcare Panellists: Bernhard Sixt, President and CEO, ImmunID Claudio Carini, Global Head of Immunology & Biomarkers, Pfizer Lisa Ricciardi, SVP, Corporate & Business Development, Foundation Medicine Thomas Tulip, President and CBO, Navidea Biopharmaceuticals 11.00 Berg LLC 11.15 BerGenBio AS 11.30 Nanobiotix SA 11.45 ImmunoVaccine Inc. 12.00 Enumeral Biomedical Holdings, Inc. 12.15 tba 12.30 tba NETWORKING LUNCH Presenting Companies TRACK B Presenting Companies TRACK C 13.45 Actinium Pharmaceuticals Fusion Pharmaceuticals 14.00 Advaxis Inc. Casi Pharmaceuticals, Inc. 14.15 Argos Therapeutics, Inc. MaxCyte, Inc. 14.30 ERYTECH Pharma SA Novogen Ltd 14.45 IMMUNE Pharmaceuticals OncoSec Medical, Inc. 15.00 Navidea Biopharmaceuticals XEME Biopharma Inc 15.15 CBM tba 15.30 CEL-SCI tba 15.45 COFFEE BREAK 16.00 Public & Private Partnerships Co-Chaired by: Lee Greenberger, Chief Scientific Officer, The Leukemia and Lymphoma Society Prem Das, Chief Business Development Officer, Dana-Farber Cancer Institute Panellists: Belen Carrillo-Rivas, Senior Director, Pfizer Darryl Mitteldorf, Executive Director, Global Prostate Cancer Alliance Fiona An, Senior Vice President, The Multiple Myeloma Research Foundation Issi Rosen, Director, Strategic Alliances, The Eli and Edythe L. Broad Institute of Harvard and MIT Juan Carlos Lopez, Head of Academic Relations & Collaborations, Roche Louise Perkins, Chief Science Officer, Melanoma Research Alliance Steven Young, President, Addario Lung Cancer Medical Institute 17.00 Investment Roundtable Co-Chaired by: Beth Jacobs, Managing Partner, Excellentia Global Partners Stuart Barich, Managing Director, Oppenheimer & Co. Inc. Panellists: Christopher Earl, Senior Advisor, Merck Research Laboratories Ventures Daniel Teper, CEO, IMMUNE Pharmaceuticals Jens Eckstein, President, S.R.One Limited John DeYoung, Vice President, Worldwide Business Development, Pfizer Philippe Muaberna, CFO, Nanobiotix Robert Urban, Head, Johnson & Johnson Innovation Todd Foley, Managing Director, MPM Capital 18.00 NETWORKING RECEPTION 19.00 END OF THE FORUM Presenting Companies TRACK D 16.00 Silence Therapeutics 16.15 immatics biotechnologies GmbH 16.30 ImmunID 16.45 NeoStem, Inc.